Skip to main content
SpringerLink
Log in

Sinnvolle komplementärmedizinische Maßnahmen in der gynäkologischen Onkologie

Reasonable complementary medicine measures in gynecological oncology

  • Frauengesundheit in der Praxis
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Die Angaben aus Studien zur Prävalenz der Inanspruchnahme von naturheilkundlichen oder komplementären Maßnahmen variieren erheblich. Für Deutschland gehen Weis et al. von einer Größenordnung von 70 % bei der Gruppe der gynäkologisch-onkologischen Mammakarzinompatientinnen aus. Der Begriff Komplementärmedizin ist noch nicht exakt definiert und sollte gegen die häufig synonym verwendeten Begriffe Alternativmedizin oder alternative Therapieverfahren abgegrenzt werden. Komplementäre Behandlungsmaßnahmen werden als erweiterte Supportivtherapie, begleitend und ergänzend zu den jeweils aktuellen konventionellen Therapiekonzepten, eingesetzt. Die Gründe für die Inanspruchnahme komplementärmedizinischer Therapien sind vielfältig, sie sind meistens in einem patienteneignen, salutogenetisch orientierten Konzept zu Gesundung, Heilung und Bewältigung der Krebserkrankung sowie zur onkologischen Therapie, zu finden. Aus Sicht der Patientinnen sind Aspekte mit hoher Priorität die Wahrung der Autonomie, die Verwirklichung einer Selbstbeteiligung und die Optimierung der Resilienz in einer kritischen, oft bedrohlichen Lebensphase, die es zu bewältigten gilt. Komplementäre Maßnahmen werden sowohl in der Akuttherapie als auch in der Nachsorge eingesetzt. Die Sicherheit und Kompatibilität der vielfältigen komplementären Maßnahmen mit der konventionellen Tumortherapie sind von größter Bedeutung.

Abstract

The results from studies on the prevalence of utilization of naturopathy or complementary medicine show substantial variation. According to Weis et al. in Germany approximately 70 % of patients with gynecological cancers, particularly patients with breast cancer, make use of complementary treatment. The term complementary medicine is not precisely defined and has to be confined to the commonly used synonymous terms alternative medicine and alternative therapy procedures. Complementary forms of treatment are utilized as extended supportive treatment options accompanying and supplementary to conventional oncological treatment. The reasons and motivations for the utilization of complementary medicine are varied and are mostly based on and characterized by the salutogenic therapy strategy of patients. This strategy supports coping, healing and overcoming the disease. From the patient perspective the aspects with the highest priority are ensuring autonomy, integration of self-participation and optimization of resilience, in a phase of life that often appears threatening and has to be overcome. Complementary therapies can be integrated into acute phase treatment and also into the rehabilitation phase. Safety and compatibility of the multitude of complementary measures with the conventional tumor treatment has the highest priority.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Andersen BL, Yang H, Farrar WB, Golden-Kreutz DM, Emery CF, Thornton LM, Young DC, Carson WE III (2008) Psychologic intervention improves survival for breast cancer patients. Cancer 113:3450–3458

    Article  PubMed  PubMed Central  Google Scholar 

  2. Babaknejad N et al (2014) The relationship between selenium levels and breast cancer: a systematic review and meta-analysis. Biol Trace Elem Res 159(1–3):1–7. doi:10.1007/s12011-014-9998-3

    Article  CAS  PubMed  Google Scholar 

  3. Bianchi G, Vitali G, Caraceni A et al (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41(12):1746–1750

    Article  CAS  PubMed  Google Scholar 

  4. Bozzetti F et al (2009) Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer 17(3):279–284. doi:10.1007/s00520-008-0476-3

    Article  PubMed  Google Scholar 

  5. Büntzel J et al (2010) Selenium substitution during radiotherapy of solid tumours – laboratory data from two observation studies in gynaecological and head and neck cancer patients. Anticancer Res 30(5):1783–1786

    PubMed  Google Scholar 

  6. Carr AC et al (2014) The effect of intravenous vitamin c on cancer-and chemotherapy-related fatigue and quality of life. Front Oncol 4:283

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cruciani RA, Dvorkin E, Homel P et al (2004) L‑carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci 1033:168–176

    Article  CAS  PubMed  Google Scholar 

  8. De Grandis D (2007) Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 21(Suppl 1):39–43

    Article  PubMed  Google Scholar 

  9. Fearon KC et al (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83(6):1345–1350

    CAS  PubMed  Google Scholar 

  10. Gröber U (2014) Arzneimittel und Mikronährstoffe, 3. Aufl. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  11. Gröber U et al (2013) Komplementärer Einsatz von Antioxidanzien und Mikronährstoffen in der Onkologie, Update 2013. Onkologe 19(2):136–143. doi:10.1007/s00761-012-2385-9

    Article  Google Scholar 

  12. Gröber U, Holzhauer P, Kisters K, Holick MF, Adamietz IA (2016) Micronutrients in oncological intervention. Nutrients 8(3):163. doi:10.3390/nu8030163

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gröber U, Kisters K, Adamietz IA (2015) Vitamin D in oncology: update 2015. Med Monatsschr Pharm 38(12):512–516

    PubMed  Google Scholar 

  14. Gröber U, Mücke R, Holzhauer P, Kisters K (2013) Micronutrients in oncology. Current data about vitamin D, selenium, L‑carnitine and vitamin C. Med Monatsschr Pharm 36(4):133–143

    PubMed  Google Scholar 

  15. Gröber U, Reichrath J, Holick MF (2015) Live longer with vitamin D? Nutrients 7(3):1871–1880. doi:10.3390/nu7031871

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hartfiel W et al (1988) Selenium deficiency in the Federal Republic of Germany. Biol Trace Elem Res 15:1–12

    Article  CAS  PubMed  Google Scholar 

  17. Henderson J, Donatelle R (2004) Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10:52–57

    PubMed  Google Scholar 

  18. Hershman DL (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31(20):2627–2633

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Holzhauer P et al (2015) Prophylaxe der Chemotherapie assoziierten oralen Mukositis. Dtsch Z Onkol 47:36–40

    Article  Google Scholar 

  20. Holzhauer P, Gröber U (2010) Checkliste: Komplementäre Onkologie. Hippokrates, Stuttgart

    Google Scholar 

  21. Jin HW, Flatters SJ, Xiao WH et al (2008) Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 210(1):229–237

    Article  CAS  PubMed  Google Scholar 

  22. Khan QJ et al (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119(1):111–118. doi:10.1007/s10549-009-0495-x

    Article  CAS  PubMed  Google Scholar 

  23. Khasabova IA (2012) Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 32(20):7091–7101. doi:10.1523/JNEUROSCI.0403-12.2012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kirchhofer B, Prävention und Management der oralen Mukositis. Workshop als PDF-Datei, http://www.tumorbiologie-freiburg.de/bilder/Download_PPT/Workshop-Mukositis-Kirchhofer.pdf. Zugegriffen: 20.09.2016

  25. Kraft M, Kraft K, Gärtner S et al (2012) L‑Carnitine-supplementation in advanced pancreatic cancer (CARPAN) a randomized multicentre trial. Nutr J 11:52

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Li WG et al (2001) Anti-inflammatory effect and mechanism of proanthocyanidins from grape seed. Acta Pharmacol Sin 22(12):1117–1120

    CAS  PubMed  Google Scholar 

  27. Ma Y et al (2014) High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6(222):222ra18. doi:10.1126/scitranslmed.3007154

    Article  PubMed  Google Scholar 

  28. Matthews A, Sellergren S, Huo D, List M, Fleming G (2007) Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med 13:555–562

    Article  PubMed  Google Scholar 

  29. Morris K, Johnson N, Homer L, Walts D (2000) A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 179:407–411

    Article  CAS  PubMed  Google Scholar 

  30. Muecke R et al (2014) Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization. Integr Cancer Ther 13(6):463–467. doi:10.1177/1534735414541963

    Article  CAS  PubMed  Google Scholar 

  31. Muecke et al (2008) Multicenter, phase-III study comparing selenium supplementation with observation in gynecologic radiation oncology. J Clin Oncol 26(15S):9539 (ASCO Abstract 2008)

    Google Scholar 

  32. Nagel G, Schreiber D (2013) Empowerment von Frauen mit Brustkrebs, 1. Aufl. Stiftung Patientenkompetenz, Freiburg

    Google Scholar 

  33. Nogues X et al (2010) Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas 66(3):291–297. doi:10.1016/j.maturitas.2010.03.012

    Article  CAS  PubMed  Google Scholar 

  34. Prieto-Alhambra D et al (2011) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125(3):869–878. doi:10.1007/s10549-010-1075-9

    Article  CAS  PubMed  Google Scholar 

  35. Rastelli AL et al (2011) Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat 129(1):107–116. doi:10.1007/s10549-011-1644-6

    Article  CAS  PubMed  Google Scholar 

  36. Rayman MP (2012) Selenium and human health. Lancet 379(9822):1256–1268

    Article  CAS  PubMed  Google Scholar 

  37. Sasagawa M, Martzen M, Kelleher W, Wenner C (2008) Positive correlation between the use of complementary and alternative medicine and internal health locus of control. Explore (NY) 4:38–41

    Article  Google Scholar 

  38. Strippoli S (2013) Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin. BMC Complement Altern Med 30(13):199. doi:10.1186/1472-6882-13-199

    Article  Google Scholar 

  39. Sayed-Ahmed MM, Salman TM, Gaballah HE et al (2001) Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy. Pharmacol Res 43(6):513–520

    Article  CAS  PubMed  Google Scholar 

  40. Singer O, Cigler T, Moore AB, Levine AB, Do HT, Mandl LA (2014) Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms. Breast J 20(2):174–179. doi:10.1111/tbj.12227

    Article  CAS  PubMed  Google Scholar 

  41. Singh S, Cuzick J, Mesher D, Richmond B, Howell A (2012) Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Res Treat 132(2):625–629. doi:10.1007/s10549-011-1911-6

    Article  CAS  PubMed  Google Scholar 

  42. Sollner W, Maislinger S, DeVries A, Steixner E, Rumpold G, Lukas P (2000) Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer 89:873–880

    Article  CAS  PubMed  Google Scholar 

  43. Thorling EB et al (1986) Selenium status in Europe – human data. A multicenter study. Ann Clin Res 18(1):3–7

    CAS  PubMed  Google Scholar 

  44. Visovsky C et al (2007) Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 11(6):901–913

    Article  PubMed  Google Scholar 

  45. Wenzel U, Nickel A, Daniel H (2005) Increased carnitine-dependent fatty acid uptake into mitochondria of human colon cancer cells induces apoptosis. J Nutr 135(6):1510–1514

    CAS  PubMed  Google Scholar 

  46. Sun Y et al (2012) A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN). J Clin Oncol 30:abstr 9017 (symptom management/supportive care/palliative care)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Onkologische Fachklinik, Onkologie und Komplementärmedizin, Klinik Bad Trissl/Innere Medizin II, Bad-Trissl-Straße 73, 83080, Oberaudorf, Deutschland

    Peter Holzhauer, Viktoria Aivazova-Fuchs & Klaus Friese

  2. Akademie für Mikronährstoffmedizin, Essen, Deutschland

    Peter Holzhauer & Uwe Gröber

Authors
  1. Peter Holzhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uwe Gröber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Viktoria Aivazova-Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Klaus Friese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Holzhauer.

Ethics declarations

Interessenkonflikt

P. Holzhauer, U. Gröber, V. Aivazova-Fuchs und K. Friese geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

K. Friese, Oberaudorf

G. Gille, Lüneburg

K. Schaudig, Hamburg

A. Schwenkhagen, Hamburg

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holzhauer, P., Gröber, U., Aivazova-Fuchs, V. et al. Sinnvolle komplementärmedizinische Maßnahmen in der gynäkologischen Onkologie. Gynäkologe 49, 805–817 (2016). https://doi.org/10.1007/s00129-016-3971-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-016-3971-5

Schlüsselwörter

Keywords

Search

Navigation